Introduction {#s1}
============

Injuries of mature central nervous system (CNS) axons result in loss of vital functions due to the failure of CNS axons to regenerate ([@bib64]; [@bib23]; [@bib20]). We and other investigators have found that the activation of phosphatidylinositol 3-kinase (PI3K) by the deletion of phosphatase and tensin homolog (PTEN) induces CNS axon regeneration through the activation of mammalian target of rapamycin (mTOR) signaling ([@bib55]; [@bib46]). PI3K is a lipid kinase, which can be activated by receptor tyrosine kinase (RTK) and subsequently phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP~2~) in the lipid membrane to produce phosphatidylinositol (3,4,5)-triphosphate (PIP~3~). PIP~3~ in turn recruits AKT, a member of the AGC family of serine/threonine kinases, to the membrane to be activated by phosphorylation at T308 via phosphoinositide-dependent kinase-1 (PDK1) ([@bib47]). PTEN is a lipid phosphatase that converts PIP~3~ to PIP~2~, and thus inhibits the activation of downstream effectors of PI3K. The PI3K-AKT pathway is the main effector by which RTKs promote cell survival and growth in response to growth factor signaling ([@bib66]). One of the multiple AKT downstream effectors is the tuberous sclerosis complex (TSC1/TSC2), the negative regulator of mTOR complex 1 (mTORC1). Thus AKT activation removes the inhibition of TSC and activates mTORC1. The PI3K-AKT-mTORC1 pathway is a master regulator of protein synthesis and cellular growth ([@bib47]; [@bib44]).

The two best characterized substrates of mTORC1 have been suggested as mediators of mTORC1's prominent roles in regulating cell growth, size, proliferation, motility and survival. One of these is the eukaryotic initiation factor 4E-binding proteins (4E-BPs); their phosphorylation releases inhibition of eukaryotic translation initiation factor 4E and initiates cap-dependent translation. The other is the ribosomal protein S6 kinases (S6Ks); their phosphorylation is critical for mRNA biogenesis, translation initiation and elongation ([@bib29]). Phosphorylation of ribosome protein S6 (pS6) by S6K has often served as a marker for mTORC1 activation. Interestingly, S6K also functions as feedback inhibition of RTK/PI3K signaling, which balances mTORC1 activation ([@bib59]; [@bib69]; [@bib74]). Both 4E-BP inhibition and S6K activation promote protein synthesis, but 4E-BPs act specifically to control cell proliferation (cell number) and S6Ks preferentially regulate cell growth (cell size) ([@bib14]; [@bib53]). We previously reported that, although S6K1 activation, but not 4E-BP inhibition, is sufficient for axon regeneration, 4E-BP inhibition is necessary for PTEN deletion-induced axon regeneration ([@bib74]). Phosphorylation and inhibition of another AKT substrate, glycogen synthase kinase 3β (GSK-3β), is critical for neuronal polarization, axon branching and axon growth ([@bib41]). However, how GSK-3β regulates peripheral axon regeneration is controversial ([@bib60]; [@bib78]; [@bib21]) and its function in CNS axon regeneration remains to be determined.

Although the mechanism is unclear, PI3K also activates mTOR complex 2 (mTORC2) in a ribosome-dependent manner ([@bib80]), which in turn phosphorylates AKT at S473 (pS473) ([@bib62]; [@bib26]; [@bib32]). pS473 enhances phosphorylation of AKT-T308 ([@bib72]; [@bib63]), and inhibition of S473 phosphorylation by destroying mTORC2 decreases AKT-T308 phosphorylation ([@bib62]; [@bib7]; [@bib77]; [@bib32]; [@bib27]). mTORC2 is involved in cell survival and actin cytoskeleton dynamics ([@bib35]) and, like mTORC1, plays a role in lipogenesis and adipogenesis ([@bib76]; [@bib43]). It is not clear how these two mTOR complexes interact to determine multiple cellular events, and this information is particularly lacking for axon regeneration.

AKT appears to be the nodal point that acts as the key substrate of both PI3K-PDK1 and PI3K-mTORC2, and is also the critical upstream regulator of mTORC1 and GSK3β. By exploiting the anatomical and technical advantages of retinal ganglion cells (RGCs) and the crushed optic nerve (ON) as an in vivo model, we elucidated the important roles of AKT, mTORC1/2 and GSK3β in adult CNS axon regeneration. Understanding this cross-regulating mechanism should provide promising therapeutic targets for CNS injuries.

Results {#s2}
=======

Three AKT isoforms display different effects on axon regeneration and RGC survival {#s2-1}
----------------------------------------------------------------------------------

To determine the role of AKT in axon regeneration, we generated adeno-associated virus 2 (AAV2) vectors containing Myr-3HA-AKT1, 2 and 3 to express membrane-bound constitutively active forms of HA-tagged AKTs in vivoWe and other investigators have demonstrated a specific tropism of AAV2 for RGCs after intravitreal injection ([@bib55]; [@bib54]; [@bib33]; [@bib6]; [@bib74]). We made AAV2-AKT viruses containing triple mutant capsid (Y444, 500, 730F) to take the advantage of the high RGC transduction efficiency of capsid-mutated AAV2 ([@bib58]): transduction exceeded 80% of RGC, based on the ratio of HA (transgene tag) to Tuj1 (antibody for RGC marker, β-III tubulin) positive cells in flat-mount retinas ([Figure 1A,B](#fig1){ref-type="fig"}). We also confirmed that all three isoforms of AKT produced the expected changes in RGCs: significantly increased levels of pAKT-S473 and pS6 (mTORC1 activation marker), indicating activation of AKT and mTORC1 ([Figure 1A,B](#fig1){ref-type="fig"}, note that pAKT-T308 antibody did not effectively immunostain retina). Western blot analysis of retina lysates showed comparable expression of AKT isoforms (HA levels), but levels of pT308 and pS6 were significantly higher in retinas transfected by AKT3 than by AKT1 ([Figure 1C,D](#fig1){ref-type="fig"}). This difference indicates the greater activity of AKT3 in retina. We noticed that both pAKT-T308 and pAKT-S473 antibodies can only be used to detect AKT1 and AKT3 reliably in Western blot, whereas the pAKT2-S474 specific antibody readily detected p-AKT2 ([Figure 1C](#fig1){ref-type="fig"}).10.7554/eLife.14908.003Figure 1.Overexpression of three constitutively active AKT isoforms in RGCs.(**A**) Confocal images of flat-mounted retinas showing co-labeling of HA tag, Tuj1, pAKT-S473 and their merged images, and pS6 in a separate retina sample. Scale bar, 20 µm. (**B**) Quantification of HA, pAKT-S473 or pS6 positive RGCs. Data are presented as means ± s.e.m, n=6. (**C**) Western blot of retina lysates from three biological replicates showing expression levels of HA-AKT isoforms, and phosphorylation levels of AKT-T308, AKT-S473 and S6. (**D**) Quantification of Western blots. \*p\<0.05. Data are presented as means ± s.e.m, n=3.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.003](10.7554/eLife.14908.003)

We then performed ON crush in wild type (WT) mice 2 weeks after intravitreal injection of these AAV-AKTs. RGC axons that regenerated through the lesion site were labeled anterogradely by intravitreal injection of the tracer Alexa 488-conjugated cholera toxin β (CTB), and imaged and quantified in ON longitudinal sections at 2 weeks post-crush ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Interestingly, the three isoforms of AKT elicited different patterns of axon regeneration: AKT2 and AKT3 caused significantly more axon regeneration than AKT1; AKT2 induced the longest axon growth ([Figure 2A,B](#fig2){ref-type="fig"}). The differing capabilities of the three isoforms of AKT in axon regeneration could not be explained simply by their expression levels, which HA staining showed to be comparable ([Figure 1C,D](#fig1){ref-type="fig"}). The higher pT308 and pS6 levels and more potent axon regeneration induced by AKT3 suggest that its function in retina differs from those of AKT1 and AKT2. Similar to their effects on axon regeneration, all three isoforms increased RGC survival to more than 40% based on Tuj1 staining in retinal flat-mounts, at least a 1-fold increase over WT mice; and significantly more RGCs survived in mice injected with AAV-AKT3 than with AKT1 ([Figure 2C,D](#fig2){ref-type="fig"}). This series of experiments demonstrated that the downstream effector of PI3K, AKT, promotes both RGC survival and ON regeneration, and that there are significant differences among the three AKT isoforms.10.7554/eLife.14908.004Figure 2.Differential effects of three AKT isoforms on axon regeneration and RGC survival.(**A**) Confocal images of ON longitudinal sections showing regenerating fibers labeled with CTB-Alexa 488 2 weeks after ON crush. Scale bar, 100 µm. \*crush site. (**B**) Quantification of regenerating fibers at different distances distal to the lesion site. Data are presented as means ± s.e.m, n=10--20. (**C**) Confocal images of flat-mounted retinas showing co-labeling of HA-AKTs and Tuj1, 2 weeks after ON crush. Scale bar, 20 µm. (**D**) Quantification of surviving RGCs, represented as percentage of Tuj1 positive RGCs in the injured eye, compared to the intact contralateral eye. Data are presented as means ± s.e.m, n=8--10. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.004](10.7554/eLife.14908.004)10.7554/eLife.14908.005Figure 2---figure supplement 1.Illustration of the regenerating axon quantification procedure.Perpendicular lines on the ON sections were drawn distal to the crush site in increments of 250 µm till 1000 µm, then every 500 µm till no fibers were visible. The regenerating fibers that crossed the perpendicular lines were counted. The width of the nerve (R) was measured at the point (d) at which the counts were taken and used together with the thickness of the section (t = 8 μm) to calculate the number of axons per µm^2^ area of the nerve. The total number of axons per section was calculated based on the formula: ∑a~d~= πr^2^ \* (axon number) / (R\*t), which then was averaged over 3 sections per animal. All CTB signals that were in the range of intensity that was set from lowest intensity to the maximum intensity after background subtraction were counted as individual fibers by Nikon NIS Element R4 software.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.005](10.7554/eLife.14908.005)10.7554/eLife.14908.006Figure 2---figure supplement 2.Endogenous expression of three AKT isoforms in RGCs.(**A**) In situ hybridization images of retina sections showing expression of three AKT isoforms in ganglion cell layer (GCL). Scale bar, 20 µm. (**B**) Western blots of retina lysates from three biological replicates showing expression of three AKT isoforms. (**C**) Confocal images of flat-mounted retinas showing co-labeling of HA tag and Tuj1. Scale bar, 20 µm. (**D**) RGC-specific ribosome-associated translating mRNA purified by Ribo-IP from three replicates of WT mice. (**E**) RNA-seq showing expression levels of three AKT isoforms in RGCs.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.006](10.7554/eLife.14908.006)

AKT1 and AKT3 are the predominant isoforms of AKT in RGCs {#s2-2}
---------------------------------------------------------

Consistent with a previous report ([@bib75]), in situ hybridization and Western blot detected all three isoforms of AKT in retina ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}). Since AKT3 is the predominant isoform in adult mouse brain (50% AKT3, 30% AKT1 and 20% AKT2) ([@bib18]), we determined whether this is also the case in RGCs. We employed the RiboTag mice, which are generated by knocking in the HA-tagged ribosome protein Rpl22 (Rpl22^HA^) to the endogenous Rpl22 allele, immediately after the floxed endogenous Rpl22 gene ([@bib61]). After intravitreal injection of AAV2-Cre, Rpl22^HA^ was expressed specifically in RGCs after Cre-mediated deletion of endogenous Rpl22 ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). This allowed us to selectively immunoprecipitate (IP) RGC-specific ribosomes (Ribo-IP) in situ ([@bib15]; [@bib30]; [@bib61]) and acquire high quality RGC-specific ribosome-associated translating mRNA from mouse retinas ([Figure 2---figure supplement 2D](#fig2s2){ref-type="fig"}). We then used three biological replicates of RGC-translating mRNAs from WT mice (8--10 mice/replicate) to perform RNA deep sequencing; each library acquired about 25 million reads and 93% of total reads aligned to unique genes in the mouse genome (mm9) by RUM ([@bib24]). Measurement of transcript abundance in fragments per Kb of exon per million fragments mapped (FPKM) ([@bib49]) indicated that AKT1 and AKT3 were the two major isoforms of AKT in RGCs; each represented 45% of total AKT, a vivid contrast to AKT2 (10%) ([Figure 2---figure supplement 2E](#fig2s2){ref-type="fig"}).

The opposite roles of phosphorylation of AKT-T308 by PDK1 and phosphorylation of AKT-S473 by mTORC2 on axon regeneration and GSK3β phosphorylation {#s2-3}
--------------------------------------------------------------------------------------------------------------------------------------------------

AKT1 and AKT3 are expressed equally in RGCs, but AKT3 is activated more potently in retina and induces better axon regeneration than AKT1. We therefore focused on AKT3 to investigate which of its domains is critical for axon regeneration. We generated three AKT3 mutants and verified their activities in RGCs after AAV infection: AKT3 kinase dead (KD) mutant (K177M), T305A/S472A (AA) mutant (equal to T308 and S473 in AKT1, T308 and S473 are used throughout the paper for convenience unless AKT3 is specified) and single T305A mutant were all equally expressed in RGCs and, as we expected, all three mutants showed significantly lower phosphorylation of T308, S473 and S6 than WT AKT3 ([Figure 3](#fig3){ref-type="fig"}). Consistent with their loss of AKT kinase function, the three mutants did not induce axon regeneration ([Figure 4A,B](#fig4){ref-type="fig"}), indicating that the phosphorylation of AKT-T308 and the kinase activity of AKT are critical for axon regeneration.10.7554/eLife.14908.007Figure 3.Over expression of three AKT3 mutants in RGCs.(**A**) Confocal images of flat-mounted retinas showing co-labeling of HA tag, Tuj1, pAKT-S473 and their merged images, and pS6 in a separate retina sample. Scale bar, 20 µm. (**B**) Western blot of retina lysates from three biological replicates showing expression level of HA-AKT, and phosphorylation level of AKT-T308, AKT-S473 and S6. (**C**) Quantification of Western blots. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. Data are presented as means ± s.e.m, n=3.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.007](10.7554/eLife.14908.007)10.7554/eLife.14908.008Figure 4.Phosphorylation of AKT3-T305 is necessary but phosphorylation of AKT3-S472 by mTORC2 is inhibitory for axon regeneration.(**A**) Confocal images of ON longitudinal sections showing lack of regenerating fibers 2 weeks after ON crush. Scale bar, 100 µm. \*crush site. (**B**) Quantification of regenerating fibers at different distances distal to the lesion site. Data are presented as means ± s.e.m, n=6--8. (**C**) Confocal images of ON longitudinal sections showing regenerating fibers labeled with CTB 2 weeks after ON crush. Scale bar, 100 µm. \*crush site. (**D**) Quantification of regenerating fibers at different distances distal to the lesion site. \*p\<0.05, \*\*\*p\<0.001. Data are presented as means ± s.e.m, n=20--30.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.008](10.7554/eLife.14908.008)10.7554/eLife.14908.009Figure 4---figure supplement 1.AAV-Cre-mediated RGC-specific deletion of *Rictor, Rptor, Mtor* or *Gsk3a* did not induce axon regeneration.(**A**) Confocal images of ON longitudinal sections showing regenerating fibers labeled with CTB, 2 weeks after ON crush. Scale bar, 100 µm. \*crush site. (**B**) Quantification of regenerating fibers at different distances distal to the lesion site. Data are presented as means ± s.e.m, n=6. \*\*p\<0.01, \*\*\*p\<0.001**DOI:** [http://dx.doi.org/10.7554/eLife.14908.009](10.7554/eLife.14908.009)10.7554/eLife.14908.010Figure 4---figure supplement 2.Translocation of AKT in ON.(**A**) Confocal images of ON longitudinal sections showing axons co-labeled with HA tag and Tuj1. Scale bar, 100 µm. (**B**) Confocal images of ON longitudinal sections showing regenerating fibers co-labeled with HA tag and CTB, 2 weeks after ON crush. Scale bar, 100 µm. \*crush site.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.010](10.7554/eLife.14908.010)10.7554/eLife.14908.011Figure 4---figure supplement 3.The effects of AKT3 mutants on RGC survival.(**A**) Confocal images of flat-mounted retinas showing Tuj1 positive RGCs, 2 weeks after ON crush. Scale bar, 20 µm. (**B**) Quantification of surviving RGCs, represented as percentage of Tuj1 positive RGCs in the injured eye, compared to the intact contralateral eye. \*p\<0.05, \*\*\*p\<0.001. Data are presented as means ± s.e.m, n=8--10.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.011](10.7554/eLife.14908.011)

We were surprised to find, however, that the AKT3-S472A mutant produced a small but statistically significant increase in axon regeneration at 500 µm distal to the crush site and a trend toward increase at other distances, compared to WT AKT3 ([Figure 4C,D](#fig4){ref-type="fig"}), suggesting that pS473 inhibits the effect of AKT on axon regeneration. This contradicts the common theme that phosphorylation of both T308 and S473 is additive to AKT activity ([@bib5]; [@bib72]; [@bib63]). To confirm this unanticipated finding, we tested whether mTORC2 also is inhibitory for AKT-induced axon regeneration, since S473 of AKT is phosphorylated by mTORC2 ([@bib62]; [@bib26]; [@bib32]). We blocked mTORC2 genetically by deleting its essential component, *Rictor* (rapamycin-insensitive companion of mTOR) ([@bib26]; [@bib44]). We injected AAV-AKT3 and AAV-Cre together into one eye of *Rictor* floxed mice and compared ON regeneration to that elicited by the injection of AAV-AKT3 alone into the contralateral eye. Consistent with our AKT3-S472A result, AKT3 and *Rictor* KO produced even more extensive and lengthier axon regeneration than AKT3 alone ([Figure 4C,D](#fig4){ref-type="fig"}). This was not due to an additive effect because *Rictor* KO alone did not cause any axon regeneration ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), but presumably through inhibition of S473 phosphorylation. Indeed, both immunostaining and Western blot analysis confirmed that AKT3-S472A mutant and *Rictor* deletion significantly decreased pS473 levels ([Figure 5A,B,F](#fig5){ref-type="fig"}). The enhanced axon regeneration was not due to increased expression of AKT3, which was slightly decreased in *Rictor* KO mice ([Figure 5B,D](#fig5){ref-type="fig"}). It was also not due to enhanced activation of AKT or mTORC1, because levels of pT308 and pS6 were also decreased ([Figure 5B,E,G](#fig5){ref-type="fig"}). This is consistent with the positive effect of pS473 on T308 phosphorylation ([@bib62]; [@bib7]; [@bib77]; [@bib32]; [@bib27]; [@bib72]; [@bib63]). Surprisingly, mTORC2 and pS473 had a negative effect on GSK3β-S9 phosphorylation; deletion of *Rictor* significantly increased pGSK3β-S9 level ([Figure 5B,H](#fig5){ref-type="fig"}). AKT3-S472A mutant also increased GSK3β-S9 phosphorylation although with large variation. *Rictor* KO alone did not increase pGSK3β-S9 compared to WT mice ([Figure 5C](#fig5){ref-type="fig"}), suggesting that AKT kinase activity is required for GSK3β phosphorylation. Since GSK3β-S9 phosphorylation has been suggested to promote peripheral axon regeneration ([@bib60]; [@bib78]), inhibition of AKT-S473 phosphorylation may increase CNS axon regeneration through enhanced inactivation of GSK3β. Taken together, our results demonstrate that, in contrast to pAKT-T308, mTORC2 and pAKT-S473 inhibit GSK3β phosphorylation, which may contribute to their negative effect on axon regeneration.10.7554/eLife.14908.012Figure 5.Increased phosphorylation of GSK3β-S9 after blocking AKT-S473 phosphorylation in RGCs.(**A**) Confocal images of flat-mounted retinas showing co-labeling of HA tag, Tuj1, pAKT-S473 and their merged images, and pS6 in a separate retina sample. Scale bar, 20 µm. (**B**) Western blots of retina lysates from three biological replicates showing expression level of HA, and phosphorylation levels of AKT-T308, AKT-S473, S6 and GSK3β-S9. (**C**) Western blots of retina lysates from three biological replicates showing phosphorylation levels of GSK3β-S9. (**D-H**) Quantification of Western blots. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. Data are presented as means ± s.e.m, n=3.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.012](10.7554/eLife.14908.012)

Since retina flat-mount preparations revealed HA signals in RGC cell bodies as well as proximal axons, we investigated the distribution of AKT in ON. All three AKT isoforms and AKT3-S472A mutant were translocated into ON. Intriguingly however, the distribution in ON of the three AKT3 mutants (KD, AA and T305A) that did not induce axon regeneration was significantly limited ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}), suggesting a local function of axonal AKT in axon regeneration. Consistent with this idea, AKT3 was also present in regenerating axons ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}).

Consistent with their loss of kinase function, the three AKT3 mutants (AKT3-KD, AA and T305A mutants) significantly decreased survival of axotomized RGCs compared to WT AKT3 ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Neither the AKT3-S472A mutant nor *Rictor* deletion significantly changed RGC survival ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}), indicating that increased axon regeneration is not due to increased neuron survival.

Taken all together, these results show that AKT kinase activity is required for both axon regeneration and RGC survival; and that phosphorylation of T308 by PI3K-PDK1 and phosphorylation of S473 by mTORC2 play opposite roles in GSK3β phosphorylation/inhibition and axon regeneration.

mTORC1 and its downstream effectors are essential for AKT3-induced axon regeneration {#s2-4}
------------------------------------------------------------------------------------

We next tested the influence of mTORC1 on AKT3-induced axon regeneration. Previous studies of mTORC1 function in axon regeneration relied on pharmacological inhibition of mTORC1 by rapamycin, which generated inconsistent or contradictory results ([@bib10]; [@bib1]; [@bib55]). To definitively determine the role of mTORC1, we disrupted mTORC1 by deleting *Rptor* (regulatory associated protein of mTOR) in RGCs specifically. *Rptor* is unique to mTORC1, and its deletion totally blocks mTORC1 activity ([@bib44]; [@bib26]). We injected AAV-AKT3 and AAV-Cre together into one eye of *Rptor* floxed mice and compared the ON regeneration to that obtained with injection of AAV-AKT3 alone into the contralateral eye. *Rptor* deletion alone did not result in axon regeneration ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}); it significantly decreased AKT3-induced axon regeneration ([Figure 6A,B](#fig6){ref-type="fig"}). The two best-characterized substrates of mTORC1, S6K1 and 4E-BP, are necessary for axon regeneration ([@bib74]; [@bib34]), we tested whether the dominant negative mutant of S6K1 (S6K1-DN) and constitutively active mutant of 4E-BP1 (4E-BP1-4A) also inhibit AKT3-induced axon regeneration. Similar to *Rptor* deletion, S6K1-DN and 4E-BP1-4A also significantly decreased AKT3-induced axon regeneration ([Figure 6A,B](#fig6){ref-type="fig"}), which further confirms the essential role of mTORC1 in AKT-induced axon regeneration. Since we found that mTORC1 is necessary but that mTORC2 is inhibitory for AKT-induced axon regeneration, we asked what the combined effect would be of blocking both mTORC1 and mTORC2 by deleting *Mtor* itself. We again injected AAV-AKT3 and AAV-Cre together into one eye of *Mtor* floxed mice and compared the ON regeneration to that obtained by injecting AAV-AKT3 alone into the contralateral eye. Deletion of *Mtor* itself did not result in axon regeneration ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) but significantly inhibited AKT3-induced axon regeneration ([Figure 6A,B](#fig6){ref-type="fig"}). This result is additional evidence for mTORC1's essential role in axon regeneration.10.7554/eLife.14908.013Figure 6.mTORC1 and its downstream effectors are essential for AKT3-induced axon regeneration.(**A**) Confocal images of ON longitudinal sections showing regenerating fibers labeled with CTB 2 weeks after ON crush. Scale bar, 100 µm. \*crush site. (**B**) Quantification of regenerating fibers at different distances distal to the lesion site. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. Data are presented as means ± s.e.m, n=8--10. (**C, D**) Western blots of retina lysates from three biological replicates showing expression levels of HA-AKT3, and phosphorylation levels of S6. (**E**) Confocal images of flat-mounted retinas showing pS6 levels and Tuj1 positive RGCs, 2 weeks after ON crush. Scale bar, 20 µm. (**F**) Quantification of surviving RGCs, represented as percentage of Tuj1 positive RGCs in the injured eye, compared to the intact contralateral eye. Data are presented as means ± s.e.m, n=8--14.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.013](10.7554/eLife.14908.013)

Consistent with its key role in protein synthesis, mTORC1 inhibition by deletion of *Rptor* or *Mtor*, or by overexpression of S6K1-DN and 4E-BP1-4A, significantly decreased the AAV-AKT3 expression ([Figure 6C,D](#fig6){ref-type="fig"}). However, RGC survival was not changed by these manipulations ([Figure 6E,F](#fig6){ref-type="fig"}), which suggests that the low level of AAV-AKT3 expression in these conditions is sufficient for its neuroprotection function in retina. The inhibitory effect of *Rptor/Mtor* KO or S6K1-DN mutant on pS6 levels ([Figure 6C--F](#fig6){ref-type="fig"}) implies that downregulation of mTORC1 activity is responsible for the decreased axon regeneration.

GSK3β phosphorylation and inhibition are necessary for AKT3-induced axon regeneration {#s2-5}
-------------------------------------------------------------------------------------

We next investigated the influence of another substrate of AKT, GSK3β. GSK3β has been suggested to negatively regulate mammalian peripheral ([@bib60]; [@bib78]) and CNS axon regeneration ([@bib12]), although contradictory result has also been reported ([@bib21]). To definitively determine the role of GSK3β in CNS axon regeneration, we used AAV-GSK3β-S9A to express a GSK3β mutant that cannot be phosphorylated and inhibited by AKT. GSK3β-S9A significantly blocked AKT3-induced axon regeneration ([Figure 7A,B](#fig7){ref-type="fig"}). Combining *Rptor* deletion with GSK3β-S9A overexpression blocked both mTORC1 activation and GSK3β inhibition, which almost totally prevented AKT3-induced axon regeneration ([Figure 7A,B](#fig7){ref-type="fig"}). These results suggest that phosphorylation and inhibition of GSK3β and activation of mTORC1 are two parallel signal pathways downstream of AKT3 that act together to influence axon regeneration.10.7554/eLife.14908.014Figure 7.GSK3β phosphorylation and inhibition by AKT is necessary and sufficient for axon regeneration.(**A,C,E**) Confocal images of ON longitudinal sections showing regenerating fibers labeled with CTB 2 weeks after ON crush. Scale bar, 100 µm. \*crush site. (**B,D,F**) Quantification of regenerating fibers at different distances distal to the lesion site. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. Data are presented as means ± s.e.m, n=8--15.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.014](10.7554/eLife.14908.014)10.7554/eLife.14908.015Figure 7---figure supplement 1.AKT3 expression and RGC survival after GSK3β manipulation.(**A**) Western blots of retina lysates from three biological replicates showing expression level of HA-AKT3. (**B**) Quantification of Western blots. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. Data are presented as means ± s.e.m, n=3. (**C**) Confocal images of flat-mounted retinas showing individual labeling of pGSK3β, pS6 and Tuj1, 2 weeks after ON crush. Scale bar, 20 µm. (**D**) Quantification of surviving RGCs, represented as percentage of Tuj1 positive RGCs in the injured eye, compared to the intact contralateral eye. Data are presented as means ± s.e.m, n=8--10.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.015](10.7554/eLife.14908.015)

*Gsk3b* deletion alone is sufficient for axon regeneration and also acts synergistically with mTORC1 and AKT {#s2-6}
------------------------------------------------------------------------------------------------------------

To determine whether GSK3β inhibition is sufficient for axon regeneration, we injected AAV-Cre into the eyes of *Gsk3b* floxed mice to delete *Gsk3b* specifically in RGCs. As [Figure 7C,D](#fig7){ref-type="fig"} shows, *Gsk3b* KO alone induced a small but significant amount of axon regeneration, in dramatic contrast to the deletion of *Gsk3a*, which yielded no axon regeneration. Deletion of both *Gsk3a* and *Gsk3b* did not have an additive effect on axon regeneration ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Since both AKT effectors, mTORC1 and GSK3β, are necessary for axon regeneration and either activation of mTORC1 effector S6K1 ([@bib74]) or *Gsk3b* deletion is sufficient to promote axon regeneration, we next tested whether these two pathways have an additive effect. This experiment showed enhancement of axon regeneration when S6K1 constitutively active mutant (S6K1-CA) was expressed in *Gsk3b* KO mice ([Figure 7C,D](#fig7){ref-type="fig"}), consistent with the idea that mTORC1 and GSK3β act in parallel, synergistic pathways downstream of AKT for axon regeneration.

Since blocking AKT-S473 phosphorylation increased GSK3β-S9 phosphorylation/inactivation ([Figure 5B,G](#fig5){ref-type="fig"}), we speculated that WT AKT alone only partially inhibits GSK3β and that AKT3 activation together with *Gsk3b* deletion would further increase axon regeneration. Indeed, regenerating axons were more numerous and longer in *Gsk3b* KO mice injected with AAV-AKT3 ([Figure 7E,F](#fig7){ref-type="fig"}), indicating incomplete inhibition of GSK3β by WT AKT3 and/or AKT-independent GSK3β activity, which acted additively with AKT-dependent GSK3β activity on axon regeneration. Consistent with this inference, AKT-independent GSK3β inactivation has been recognized in peripheral axon regeneration ([@bib78]).

Although AKT3 levels were variable after *Gsk3b* and/or *Rptor* manipulation ([Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}), RGC survival induced by AKT3 was unchanged ([Figure 7---figure supplement 1C,D](#fig7s1){ref-type="fig"}), indicating sufficient AKT3 expression in retina for neuroprotection. In fact, even though expression of AKT3 was also lower in *Gsk3b* KO mice, axon regeneration was enhanced ([Figure 7E,F](#fig7){ref-type="fig"}). Thus, the changes in axon regeneration depend on signaling cross-talk and alterations of pS6 and pGSK3β-S9 ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}), but not on the absolute levels of AKT3.

Discussion {#s3}
==========

Although AKT has been linked with axon growth in vitro ([@bib65]; [@bib37]; [@bib48]) and axon regeneration in vivo ([@bib67]; [@bib50]; [@bib40]), there is surprisingly little information about the specificity of AKT isoforms and the role of different phosphorylation sites of AKT (T308 and S473) in axon regeneration. In contrast to AKT1 and AKT2, which are widely expressed, AKT3 is the predominant isoform in brain ([@bib18]). Deletion of AKT1 reduces whole body size and deletion of AKT2 results in diabetes-like syndrome ([@bib8]; [@bib9]). Deletion only of AKT3 specifically reduces brain size ([@bib18]), indicating a specific role of AKT3 in regulation of CNS growth. Interestingly, AKT2 and AKT3, but not AKT1, regulate survival and growth of cultured hippocampal neurons ([@bib11]). Our analysis of the expression levels of the three AKT isoforms in RGCs and their distinct roles in axon regeneration provides additional in vivo evidence of the unique properties of AKT3 in CNS: AKT3 activation promotes significantly greater RGC survival and ON regeneration than AKT1, presumably through its unique ability to activate mTORC1 (higher pS6) in retina. This is also true in brain as AKT3 KO, but not AKT1 deletion, decreases pS6 significantly ([@bib18]). AKT3 may also selectively activate unknown, neuronal-specific signaling molecules. The partial functional redundancy of AKT isoforms, however, makes identification of these molecules difficult ([@bib17]).

We found that mTORC1 inhibition (*Rptor* or *Mtor* deletion, S6K1-DN or 4E-BP1-4A over-expression) decreased AKT3 expression ([Figure 6C,D](#fig6){ref-type="fig"}). Decreased AKT3 by itself may not account for reduced axon regeneration, however, because the remaining amounts enabled RGCs to survive ([Figure 6E,F](#fig6){ref-type="fig"}). Although we cannot exclude the possibility that the decrease in AKT3 contributed to the reduced axon regeneration, we consider the significant decreases in mTORC1 signaling and protein synthesis to be the main reason for the inhibition of axon regeneration. This notion receives additional support from our observation of other conditions in which axon regeneration was enhanced despite downregulation of AKT3 ([Figure 4C,D](#fig4){ref-type="fig"} and [Figure 7E,F](#fig7){ref-type="fig"}), which suggests that high levels are not required for axon regeneration. Based on our previous demonstration of the necessary role of 4E-BP and S6K1 ([@bib74]),we therefore conclude that mTORC1 is critically important for axon regeneration and that the effects on axon regeneration are due to the signaling alterations, rather than to the changed levels of AKT expression per se.

Our observation of enhanced axon regeneration by AKT3-S472A mutant and *Rictor* KO suggests that pS473 either inhibits phosphorylation of T308 directly or allows AKT to activate distinct substrates that are different from those of pT308, which are inhibitory for axon regeneration. Our finding that pS473 enhances, rather than inhibits, phosphorylation of T308, implies that different substrates or differentially regulated substrates by pT308 and pS473, must contribute to the difference in axon regeneration. The inhibitory effect of mTORC2 and pAKT-S473 on GSK3β phosphorylation is striking and very interesting. The significantly increased pGSK3β-S9 after blocking mTORC2 and S473 phosphorylation suggests that GSK3β is one of the AKT effectors that are differentially regulated by pAKT-T308 and pAKT-S473. Although previous in vitro study showed unchanged GSK3β phosphorylation after *Rictor* KO and reduced S473 phosphorylation ([@bib26]), the liver or muscle-specific *Rictor* deletion increases GSK3β phosphorylation ([@bib42]; [@bib77]). The results of our studies using GSK3β-S9A mutant and *Gsk3b* KO mice provide additional evidence of the inhibitory role of GSK3β in axon regeneration and definitively resolve the contradictory information in the literature ([@bib10]; [@bib1]; [@bib60]; [@bib12]; [@bib21]). In vitrokinase assay will be necessary to definitively demonstrate the roles of pAKT-T308 and pAKT-S473 in GSK3β-S9 phosphorylation, We have shown that pAKT-T308 and pAKT-S473 regulate the inhibition and phosphorylation of retinal GSK3β in opposite directions. This process acts in parallel with another AKT downstream effector, mTORC1, to regulate CNS axon regeneration ([Figure 8](#fig8){ref-type="fig"}). Interestingly, downstream effectors that are specific to mTORC2-pAKT-S473 but not to pAKT-T308 have been proposed ([@bib26]; [@bib73]; [@bib35]; [@bib36]; [@bib25]), consistent with the notion that pAKT-S473 regulates β-cell proliferation whereas pAKT-T308 controls β-cell size ([@bib25]; [@bib28]).

The balance between pro-regeneration pT308 and anti-regeneration pS473 forms of AKT appears to be critical. Our observation that *Rictor* deletion induces more potent axon regeneration with a smaller decrease in pS473 and pT308 than AKT3-S472A mutant ([Figure 5](#fig5){ref-type="fig"}) may indicate a better therapeutic strategy for manipulating AKT signaling to promote axon regeneration. It is also worth noting that, because *Rictor* deletion did not totally block AKT-S473 phosphorylation, other kinases in addition to mTORC2 may contribute in retina. Moreover, because other kinases have been suggested to phosphorylate GSK3β-S9 in addition to AKT ([@bib68]; [@bib19]; [@bib2]), it will be important to investigate whether these kinases are also regulated by mTORC2 in a similar way as AKT. Since mTORC2 and pAKT-S473 are necessary for PTEN deletion-induced tissue overgrowth in drosophila eyes ([@bib31]) and development of prostate cancer in mouse ([@bib27]), targeting/blocking mTORC2 may allow us to boost PTEN/AKT's regeneration-promoting effect while at the same time minimizing its deleterious tumorigenic effect.10.7554/eLife.14908.016Figure 8.A schematic illustration depicting the interplay between AKT, mTORC1/2 and GSK3β in CNS axon regeneration.The predominant isoform of AKT in brain and retina, AKT3, generates the most robust axon regeneration. Its function in axon regeneration is positively regulated by the PI3K/PDK1 pathway through phosphorylation of T308 (T305 in AKT3), and negatively regulated by the PI3K/mTORC2 pathway through phosphorylation of S473 (S472 in AKT3), through at least partially regulation of GSK3β phosphorylation and inhibition. Both AKT downstream effectors, activation of mTORC1 and phosphorylation/inhibition of GSK3β, synergistically promote axon regeneration; inhibition of GSK3β alone is also sufficient for axon regeneration. The question mark represents other upstream regulators of GSK3β that may also promote axon regeneration. Green color-coated molecules are pro-axon regeneration and dark color-coated molecules are anti-axon regeneration.**DOI:** [http://dx.doi.org/10.7554/eLife.14908.016](10.7554/eLife.14908.016)

Apparently, neuronal survival is a prerequisite for axon regeneration. But we and others did not find that increased neuron survival was invariably linked to proportionately greater axon regeneration ([@bib4]). This is consistent with findings in other systems. For example, most corticospinal neurons exhibit long term survival after transection in the spinal cord ([@bib51]; [@bib52]), but they fail to regenerate axons ([@bib64]; [@bib23]; [@bib20]). The 20% of RGCs that normally survive ON crush in mice can be increased significantly by inhibition of apoptosis, deleting tumor suppressor genes or by manipulating ER stress pathways, but these manipulations do not necessarily induce ON regeneration ([@bib55]; [@bib33]; [@bib22]). This observation indicates that axon regeneration requires neuronal intrinsic growth stimulators that are distinct from neuronal surviving factors. Thus we consistently found that, although manipulation of mTOR complexes and GSK3β significantly changed axon regeneration, RGC survival induced by AKT remained the same. We could not exclude the possibility that changing RGC survival contributed to a change in axon regeneration, but no convincing evidence proves a direct causative relationship between these two events. The available evidence, therefore, supports the idea that the intrinsic signaling events after AKT activation and the involvement of its upstream or downstream signaling effectors are directly related to intrinsic growth control of neurons, and that these signaling pathways are distinct from or overlap only partially, signaling necessary for survival. There are far fewer regenerating axons than surviving RGCs, however, suggesting that only a small percentage of RGCs are regenerating and different subtypes of RGCs have different regeneration abilities ([@bib16]). In-depth understanding of the mechanisms of this difference will be required to maximize RGC axon regeneration.

Increasing evidence has demonstrated the importance of localized protein synthesis in peripheral axon regeneration ([@bib71]; [@bib38]; [@bib57]). Intra-axonal translation has recently been demonstrated in mature mouse hippocampus ([@bib3]) and, more intriguingly, certain mRNA species and additional components of translation machinery, including pS6 and 4E-BP1, have been detected in regenerating axons in rat spinal cord ([@bib39]). Since we also observed that regeneration-promoting WT AKTs and AKT-S473A mutant were localized in ON whereas non-regeneration AKT mutants were excluded from ON, it will be very intriguing to investigate the significance of axonal AKT activation in CNS axon regeneration, especially its effect on axonal protein synthesis.

In summary, our genetic manipulations in RGCs have established that the activation of mTORC1 and inhibition of GSK3β are two critical pathways downstream of AKT that act in parallel and synergistically to promote CNS axon regeneration ([Figure 8](#fig8){ref-type="fig"}). The opposite effects of mTORC1 and mTORC2 on axon regeneration suggest that a balancing mechanism exists downstream of the critical growth-promoting signal PI3K and that AKT integrates both positive and negative signals through phosphorylation of T308 and S473 and their specific roles in downstream effectors mTORC1 and GSK3β to control CNS axon regeneration ([Figure 8](#fig8){ref-type="fig"}). Interestingly, mTORC1/S6K also functions as feedback inhibition of PI3K signaling ([@bib44]), which also balances AKT activation and axon regeneration ([@bib74]). Thus, it is reasonable to expect that the increased understanding of the complicated cross-regulation and feedback-control mechanisms presented by our studies will eventually lead to safe and effective therapeutic strategies for CNS injury.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

*Rictor*^flox/flox^, *Rptor*^flox/flox^, *Mtor*^flox/flox^ and RiboTagmice with C57BL/6 background and C57BL/6 WT mice were purchased from Jackson Laboratories (Bar Harbor, Maine). *Gsk3b*^flox/flox^ and *Gsk3a*^flox/flox^ mice with C57BL/6 background were originally developed by Dr. Jim Woodgett ([@bib13]; [@bib56]) and were acquired from Dr. Thomas Force. We crossed them to generate *Gsk3a/b*^flox/flox^ mice. All experimental procedures were performed in compliance with animal protocols approved by the IACUC at Temple University School of Medicine. For all surgical and treatment comparisons, control and treatment groups were prepared together in single cohorts, and the experiment repeated at least twice.

Constructs {#s4-2}
----------

pcDNA3-Myr-HA-AKT1 (\#9008), pcDNA3-Myr-HA-AKT2 (\#9016), pcDNA3-Myr-HA-AKT3 (\#9017) and pcDNA3-HA-GSK3β-S9A (\#14754) were obtained from Addgene. We used overlap PCR method to produce AKT3 mutants AKT3-T305A, AKT3-S472A, AKT3-T305A/S472A (AKT3-AA), AKT3-K177M (AKT3-KD) and subcloned the WT AKT1-3 and AKT3 mutants into an AAV backbone that contained CBA promoter with Myr-3xHA tag at the N-terminus to get AAV-Myr-3HA-AKT1-3 and AKT3 mutants. We generated AAV-3HA-GSK3β-S9A similarly and AAV-Cre, AAV-S6K1-DN, AAV-S6K1-CA and AAV-4E-BP1-4A were described before ([@bib74]).

AAV production {#s4-3}
--------------

The detailed procedure has been described previously ([@bib33]; [@bib74]). Briefly, AAV plasmids containing the transgenes were co-transfected with pAAV2 (pACG2)-RC triple mutant (Y444, 500, 730F) ([@bib58]; [@bib70]; [@bib79]) and the pHelper plasmid (Stratagene, La Jolla, California) into HEK293T cells. 72 hr after transfection, the cells were lysed to release the viral particles, which were precipitated by 40% polyethylene glycol and purified by cesium chloride density gradient centrifugation. The fractions with refractive index from 1.370 to 1.374 were taken out for dialysis in MWCO 7000 Slide-A --LYZER cassette (Pierce, Thermo Fisher Scientific, Waltham, Massachusetts) overnight at 4°C. The AAV titers that we used for this study were in the range of 1.5--2.5 x 10^12^ genome copy (GC)/ml determined by real-time PCR.

Intravitreal injection and ON crush {#s4-4}
-----------------------------------

Mice were anesthetized by xylazine and ketamine based on their body weight (0.01 mg xylazine/g+0.08 mg ketamine/g). For each AAV intravitreal injection, a micropipette was inserted into the peripheral retina of 3 week-old mice just behind the ora serrata, and advanced into the vitreous chamber so as to avoid damage to the lens. Approximately 2 µl of the vitreous was removed before injection of 2 µl AAV into the vitreous chamber. ON crush was performed 2 weeks following AAV injection: the ON was exposed intraorbitally and crushed with a jeweler's forceps (Dumont \#5; Fine Science Tools, Forster City, California) for 5 s approximately 0.5 mm behind the eyeball. Care was taken not to damage the underlying ophthalmic artery. Eye ointment containing neomycin (Akorn, Somerset, New Jersey) was applied to protect the cornea after surgery.

RGC axon anterograde tracing {#s4-5}
----------------------------

2 µl of cholera toxin β subunit (CTB) conjugated with fluorescence Alexa- 488 (2 μg/μl, Invitrogen) was injected into the vitreous chamber 2 days before sacrificing the animals to label the regenerating axons in the optic nerve. Animals were sacrificed by CO~2~ and fixed by perfusion with 4% paraformaldehyde in cold PBS. Eyes with the nerve segment still attached were dissected out and post-fixed in the same fixative for another 2 hr at room temperature. Tissues were cryoprotected through increasing concentrations of sucrose (15%-30%) and optimal cutting temperature compound (OCT) (Tissue Tek, Sakura Finetek, Torrance, California). They were then snap-frozen in dry ice and serial longitudinal cross-sections (8 µm) were cut and stored at --80°C until processed.

Immunohistochemistry of flat-mount retina {#s4-6}
-----------------------------------------

Retinas were dissected out from 4% PFA fixed eyes and washed extensively in PBS before blocking in staining buffer (10% normal goat serum and 2% Triton X-100 in PBS) for 30 min. Mouse or rabbit neuronal class ß-III tubulin (clone Tuj1, 1:500; Covance, Conshohocken, Pennsylvania), rat HA (clone 3F10, 1:200, Roche, Basel, Switzerland), phospho-S6-Ser240/244 antibody (1:200, \#5364, Cell Signaling, Danvers, Massachusetts), phospho-AKT-Ser473 (1:200; \#4058, Cell Signaling) and phospho-GSK-3β (Ser9) (1:100; \#9323, Cell Signaling) were diluted in the same staining buffer. Floating retinas were incubated with primary antibodies overnight at 4°C and washed three times for 30 min each with PBS. Secondary antibodies (Cy2, Cy3 or Cy5-conjugated) were then applied (1:200; Jackson ImmunoResearch, West Grove, Pennsylvania) and incubated for 1 hr at room temperature. Retinas were again washed three times for 30 min each with PBS before a cover slip was attached with Fluoromount-G (Southernbiotech, Birmingham, Alabama).

Western blot {#s4-7}
------------

Retinas were dissected out from ice-cold PBS perfused eyes and homogenized and lysed in RIPA buffer (50 mM Tris HCl pH8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 5 mM sodium pyrophosphate, 10 mM sodium fluoride, 1 mM sodium orthovanadate, protease inhibitors cocktail) on ice for 30 min. The homogenates were centrifuged at 12,000 g for 20 min; supernatants were subjected to electrophoresis with 10% SDS-PAGE. After gel-transference, nitrocellulose membranes were blocked with Odyssey blocking buffer (LI-COR, Lincoln, Nebraska) for 1 hr before incubation with primary antibody at 4°C overnight. After washing three times for 10 min with PBS, the membranes were incubated with secondary antibodies (IRDye 680RD goat-anti-mouse IgG or IRDye 800CW goat-anti-rabbit IgG, LI-COR) at room temperature for 1 hr. The membranes were then washed three times for 10 min with PBS and scanned with Odyssey CLx (LI-COR). The images were analyzed with Image Studio (LI-COR). The primary antibodies used were mouse HA (clone 16B12, 1:2000, Covance), mouse Anti-β-Actin(clone AC-15, 1:2000, Sigma, St Louis, Missouri), and antibodies from Cell Signaling: rabbit phospho-AKT Thr308 (1:500, \#2965), rabbit phospho-AKT Ser473 (1:1000, \#4058), rabbit phospho-AKT2 Ser474 (1:1000, \#8599), rabbit phospho-S6 Ribosomal Protein Ser240/244 (1:1000, \#5364), rabbit phospho-GSK-3β Ser9 (1:500; \#9323), mouse S6 Ribosomal Protein (1:500, \#2317) and mouse GSK-3β (1:500, \#9832).

In situ hybridization {#s4-8}
---------------------

After adult 8-week old mice were perfused with ice-cold 4% PFA/PBS, eyeballs were dissected out and fixed in 4% PFA/PBS at 4°C overnight. The eyeballs were dehydrated with increasing concentrations of sucrose solution (15%-30%) overnight before embedding in OCT on dry ice. Serial cross sections (12 µm) were cut with a Leica cryostat and collected on Superfrost Plus Slides. The sections were washed twice for 10 min in DEPC-treated PBS and permeabilized twice in 0.1% Tween/PBS for 10 min. After blocking at 50°C for 1 hr with hybridization buffer (50% formamide, 5 x SSC, 100 μg/ml Torula Yeast RNA, 100 μg/ml Wheat Germ tRNA, 50 μg/ml heparin and 0.1% Tween in DEPC H~2~O), the sections were hybridized with 2 µg biotin-labeled antisense probes at 50°C overnight. The sections were washed three times at 55°C for 10 min with hybridization buffer, 0.1% Tween/PBS, and then blocked in PBS blocking buffer containing 0.1% BSA and 0.2% TritonX-100. The hybridized probes were detected by Streptavidin-AP-conjugate (Roche), and revealed by chromogenic substrate NBT/BCIP (Roche). Mouse AKT1, 2, 3 probe sequences were from Allen Brain Atlas (<http://mouse.brain-map.org/>).

Counting surviving RGCs and regenerating axons {#s4-9}
----------------------------------------------

For RGC counting, whole-mount retinas were immunostained with the Tuj1 antibody, and 6--9 fields were randomly sampled from peripheral regions of each retina. The percentage of RGC survival was calculated as the ratio of surviving RGC numbers in injured eyes compared to contralateral uninjured eyes. For axon counting, the number of CTB- labeled axons was quantified as described previously ([@bib45]; [@bib55]; [@bib74]). Briefly, we counted the fibers that crossed perpendicular lines drawn on the ON sections distal to the crush site in increments of 250 µm till 1000 µm, then every 500 µm till no fibers were visible ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The width of the nerve (R) was measured at the point (d) at which the counts were taken and used together with the thickness of the section (t = 8 μm) to calculate the number of axons per µm^2^ area of the nerve. The formula used to calculate is ∑a~d~= πr^2^ \* (axon number) / (R\*t). The total number of axons per section was then averaged over 3 sections per animal. All CTB signals that were in the range of intensity that was set from lowest intensity to the maximum intensity after background subtraction were counted as individual fibers by Nikon NIS Element R4 software. The investigators who counted the cells or axons were blinded to the treatment of the samples.

Ribo-IP and RNA-sequencing (RNA-seq) {#s4-10}
------------------------------------

Three groups of RiboTag mice (8--10 mice/group) were intravitreally injected with AAV2-Cre four weeks before sacrifice and removal of retinas. Ribo-IP was performed according to the published protocol ([@bib61]). Briefly, for each replicate, 10--16 pooled retinas were homogenized and lysed in 1 ml homogenization buffer (50 mM Tris pH7.4, 100 mM KCl, 12 mM MgCl, 1% NP-40, 1 mM DTT, 100 μg/ml cyclohexamide, 1 mg/ml heparin, Protease Inhibitor Cocktail (Sigma) and RNasin Ribonuclease Inhibitor (Promega Corp., Madision, Wisconsin) in RNase-free H2O) on ice for 10 min and centrifuged at 4°C for 10 min at 12,000 g. The supernatant was collected and incubated at 4°C for 4 hr with 10 µg mouse HA antibody, after which 400 μl Dynabeads Protein G (Life Technologies, Frederick, Maryland) were added and incubation continued at 4°C overnight. Dynabeads were washed three times for 10 min with high salt buffer (50 mM Tris pH7.4, 300 mM KCl, 12 mM MgCl, 1% NP-40, 1 mM DTT and 100 μg/ml Cyclohexamide in RNase-free H2O) before RNA extraction with RNeasy Micro Kit (QIAGEN, Hilden, Germany). About 200ng total RNA generated from each group was used for RNA-seq, which was done at the University of Pennsylvania Next-Generation Sequencing Core. Briefly, Ribo-IP RNA samples from three biological replicates went through polyA selection before the generation of strand-specific RNA-seq libraries with Illumina TruSeq Stranded Total Kit and quality assessment with Agilent BioAnalyser and Kapa BioSystems Library Quant Kit. Pooled libraries that have been individually labeled were sequenced to 100 bp reads from one end of the insert using a HiSeq2000 sequencer. Each library acquired about 25 million reads and 93% of total reads aligned to unique genes in the mouse genome (UCSC mm9) by RUM ([@bib24]). The \'raw\' data (reads per transcript) were quantile normalized within groups with quantile normalization (GCRMA) to remove non-biological variability.

Statistical analyses {#s4-11}
--------------------

Data are presented as means ± s.e.m and Student's t-test was used for two-group comparisons and One-way ANOVA with Bonferroni's post hoc test was used for multiple comparisons.
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Congratulations: we are very pleased to inform you that your article, \"mTORC1 Is Necessary But mTORC2 And GSK3β Are Inhibitory For AKT3-Induced CNS Axon Regeneration\", has been accepted for publication in *eLife*. The Reviewing Editor for your submission was Nahum Sonenberg and the Senior Editor was K VijayRaghavan. Please note the suggested changes indicated by reviewers \#1 and 2 below. If you wish to make these changes, please let us know and we will be happy to consider a final version without returning the manuscript to the reviewers.

Reviewer \#1:

In this revised manuscript, the authors have addressed the majority of my concerns. They include quantification of protein expression levels as well as quantification of axon regeneration with different manipulations. The new findings included with the RiboTag mice and the localization of Akt in the axon are interesting. Overall, the manuscript reads better in its revised form, and the observations are presented in a more convincing way.

One control that is important for the new [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"} is to show the levels of these Akt isoforms/mutants in the cell bodies by western blotting of the corresponding retinas. It is essential to show that the absence of signal in the axon is not due to lower expression levels in the cell body.

Reviewer \#2:

The manuscript is overall much improved from its original submission. The changes made in response to the reviewers' comments have clarified a number of issues. I appreciate the authors including the RGC survival data throughout the work -- I think that strengthens the manuscript quite a bit and supports the authors\' conclusions for role of AKT3→Torc1 in regeneration. While there certainly are many instances where injured neurons survive but do not regenerate, I do not know of anywhere they regenerate in the absence of survival, Despite the improvement, I think there are a remaining few points of confusion and ambiguity in the data that the authors overlook in interpreting the work. Many of these could be addressed with text changes and some additional controls in the figures.

In [Figure 1](#fig1){ref-type="fig"} there is a remarkable increase in pAKT2-S474 with the myr-AKT2 overexpression. One has to wonder if this is just different affinity between pS474 and pS473 antibodies? However, more concerning is that the authors indicate that transduced myr-AKT3 affords greater regeneration and the endogenous AKT3 is predominant over AKT2. [Figure 2](#fig2){ref-type="fig"} shows that transduced myr-AKT2 provides as good or better regeneration activity than AKT3 and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} shows quite prominent ISH signals and immunoblotting signals for all three isoforms. Granted the RNA-seq data from RGCs shows different loading of AKT1-3 on ribosomes, but I do not think the authors can dismiss the data on regeneration with transduced myr-AKT2 and expression of endogenous AKT2 as they have. This does not detract from the manuscript\'s findings, but I think the authors should not be misrepresenting their data to the reader (e.g., sentence "The higher pT308 and pS6 levels and more potent axon regeneration induced by AKT3 suggest that its function in retina differs from those of AKT1 and AKT2" is not valid).

The increased regeneration of AKT-S472A vs. WT noted for [Figure 4](#fig4){ref-type="fig"} only appears to be significant for 500 µm distance. Perhaps the authors should note that the remainder show a trend.

In the last paragraph of the subsection "mTORC1 and its downstream effectors are essential for AKT3-induced axon regeneration", the authors describe the decreased AKT3 expression with S6K-DN and 4E-BP1-4A expression suggesting that the low level of AKT3 is sufficient for (survival) function in the retina. Decrease in AKT3 is also seen for RICTOR KO in [Figure 5D](#fig5){ref-type="fig"} but not described. For both of these situations, I think the authors need to be clear that they are referring to levels of the transduced AKT3 not endogenous. Also the authors should indicate that this could reflect a direct effect on protein synthesis as they imply in the aforementioned paragraph, but could also be secondary to altered levels of viral transduction. Both here and in the subsection "GSK3β deletion alone is sufficient for axon regeneration and also acts synergistically with mTORC1 and AKT", the authors should clarify that they are referring to AKT3 executing a survival function in the cell body rather than distinguishing between soma and axon intrinsic actions of AKT3. Speculation on this difference is more appropriate for the Discussion as the authors have included in this revised version.

Reviewer \#3:

The authors have made a comprehensive response to each of the points raised by the reviewers. Most of the points have been fully addressed.

I do not have any further comments.

\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The previous decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"mTORC1 Is Necessary But mTORC2 and GSK3β Are Inhibitory For AKT3-Induced CNS Axon Regeneration\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and K VijayRaghavan as the Senior Editor. Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

The authors investigated the signaling pathways playing a role in retinal axon regeneration. It was previously shown that PTEN deletion promotes axon regeneration. Here, the authors study Akt isoforms, mTOR complexes 1 and 2, and downstream S6K and 4EBP using the same in vivo assay. They conclude that Akt3 more than other Akt isoforms is sufficient for regeneration. Similarly, RAPTOR and mTOR are necessary and RICTOR is inhibitory for Akt3-mediated regeneration. Finally, GSK3β and mTORC1 appear to be parallel pathways contributing to retinal axon regeneration.

Overall, the experiments probe an important gap in our understanding of the cellular signaling pathways that mediate retinal axon regeneration. These intrinsic signaling mechanisms likely play a role not only downstream of PTEN deletion but possibly other regeneration-inducing treatments as well. We are turning this paper down because a thorough and complete addressing of the major concerns will take time, and, when done, will result in a substantively different manuscript.

Reviewer \#1:

In this manuscript, Miao et al. investigate the signaling pathways playing a role in retinal axon regeneration. It was previously shown that PTEN deletion promotes axon regeneration. Here, the authors study Akt isoforms, mTOR complexes 1 and 2, and downstream S6K and 4EBP using the same in vivo assay. They conclude that Akt3 more than other Akt isoforms is sufficient for regeneration. Similarly, RAPTOR and mTOR are necessary and RICTOR is inhibitory for Akt3-mediated regeneration. Finally, GSK3β and mTORC1 appear to be parallel pathways contributing to retinal axon regeneration.

Overall, the experiments probe an important gap in our understanding of the cellular signaling pathways that mediate retinal axon regeneration. These intrinsic signaling mechanisms likely play a role not only downstream of PTEN deletion but possibly other regeneration-inducing treatments as well.

My main concern about the in vivo experiments is the lack of quantification and controls with respect to the expression of the constructs, especially Akt isoforms and mutants. This raises the question of whether the effects observed are truly due to gene manipulation or due to alterations in the expression of exogenous construction at different levels. Addressing these two important gaps (quantification of cell signaling alterations and quantification of expression levels of tagged proteins) would significantly enhance the impact of this manuscript.

1\) If the authors are going to refer to [Figure 3C](#fig3){ref-type="fig"} in the Introduction, I suggest that they move it to [Figure 1](#fig1){ref-type="fig"}.

2\) [Figure 1C](#fig1){ref-type="fig"}: The authors need to quantify expression levels of HA-tagged AKt isoforms. Also since Ser 235-236 phosphorylation is not specific to S6K, please measure phospho-S6 at Ser 240-244 (antibody available from Cell signaling).

3\) [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}: same criticism as above. Needs quantification of Akt mutants and phospho-S6 at Ser 240-244.

4\) [Figure 3](#fig3){ref-type="fig"}: It is especially important in this figure to know what the expression levels of Akt3 exogenous construct is in each of these conditions. The effects of mTOR or RAPTOR knockout could simply affect the expression levels of Akt3.

5\) [Figure 4](#fig4){ref-type="fig"}: similar concerns as above. The authors need to show and quantify the expression levels of Akt3 expression constructs in 4B, E and F.

Reviewer \#2:

In this short research report, Miao et al. focus on differential regulation of AKT→mTor pathways for CNS axon regeneration using an optic nerve crush model. The authors convincingly show that membrane targeted AKT proteins increase regeneration, with AKT2 and 3 driving higher levels of growth than AKT1. The differential effects of mTORC1 vs. mTORC2 are intriguing and, if true, have important implications for efforts in the field to augment CNS regeneration using activation of AKT→mTor pathway. Likewise, differential activity of AKT3PT305 vs. AKT3PS472 is a novel finding and a potential advance. Overall, the authors conclude that AKT3PT305→GSK3βPS9 and mTORC1→4EBP1/S6K support CNS axon regeneration while mTORC1→AKT3PS472 blocks or antagonizes axon regeneration. However, I am not convinced that the authors have proven these conclusions.

RGC death following axotomy is well established and the authors indicate that introduction of the AKTmyr isoforms increased RGC survival roughly two fold over non-transduced animals/eyes. The authors sporadically mention survival differences in the text, but show no other data beyond [Figure 1D](#fig1){ref-type="fig"}. Looking over the post-crush retina images, there is quite variable Tuj1 staining in the supplemental figures. For example, Figure 3---figure supplement 2 shows markedly different numbers of Tuj1+ cells comparing AKT3 only vs. additional AKT3 + raptor KO, S6K-DN, 4EBP1S4A(?) & mTOR KO; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"} similarly shows differences in RGC numbers with Tuj1 staining comparing the varying combinations. Considering that the authors only show naïve retina images for the AKT3 mutants and Rictor-KO, I have a very difficult time dissociating regeneration and survival based on the data presented. Obviously, the RGCs need to survive after axotomy to regenerate, but I have concern that some of the decreased regeneration here may relate to differences in survival with the AKT, mTOR, and GSK3β manipulations. The authors need to provide quantitative data for survival across these manipulations and offer clear evidence that effects are regeneration rather than RGC survival to support their conclusions. Going along with this, some of the supplemental data should likely be included in the regular figures for the manuscript.

Similar to the above issue with survival images, the immunoreactivity for pS6K and pGSK3β varies substantially across the same supplemental images and the authors seem to cherry-pick the relevance of these variations.

With the exception of Figure 1---figure supplement 1, the authors do not show any data on wild-type retina/optic nerve. Considering that *eLife* presumably targets a general readership (i.e., rather than selectively neuroscience), the authors need to include data on wild-type animal responses -- or better yet, rodents transduced with a control AAV2.

The authors\' conclusion that T305 and S472 phosphorylation have distinct outcomes for regeneration is quite intriguing. The schematic in [Figure 3C](#fig3){ref-type="fig"} suggests that mTORC2 has a more direct effect on attenuating axon regeneration than antagonizing phosphorylation of AKTT473. If this is the case, then why would the RICTOR KO have no effect on regeneration by itself? Also, when the authors claim that no axon regeneration was detected in mTOR KO, RAPTOR KO, RICTOR KO, against what are the comparisons being performed? It would be useful to see the quantitation of this growth compared to both control viral transduction and wild type AKT3 -- likewise, quantitation of the axon growth with the varying AKT3 mutants should be shown.

It is unfortunate that the anti-phospho-AKTT308 does not recognize AKT3PT305, as I think that distinguishing an intramolecular inhibition of T305 phosphorylation vs. indirect mechanisms (including intermolecular between AKT proteins) is an important distinction to make. I do not think it is necessarily needed for the current manuscript, but it would be good to know what efforts the authors made to detect AKT3PT305 as positive data could strengthen the authors\' case.

From the work here, as well as previous observations from this group, it is not clear if the effect of modulating the AKT→mTor pathway is mediated in the perikaryon, locally in the axons/growth cones, or both. With increasing evidence for localized protein synthesis in regenerating axons and recent work showing mRNAs and translational machinery (including the mTORC1 targets studied here) in regenerating CNS axons, the authors should acknowledge the possibility of localized effects. The images for HA shown in [Figure 1](#fig1){ref-type="fig"} suggest that AKTmyr isoforms are localizing into at least the proximal axons. Do these also extend to the distal regenerating axons? This also raises the question of whether the regenerating axons shown with CTB labeling are also HA positive (i.e., for those animals expressing AKT isoforms).

Reviewer \#3:

The paper looks at AKT and GSKβ effects on regeneration in the optic nerve, assigning roles to various components of the signaling pathway.

1\) The authors state at the beginning that they achieved 90% transduction of ganglion cells, but do not appear to have measured this routinely in each case. 90% transduction over the whole retina is difficult to achieve. Moreover, some of the illustrations suggest that the transduction rate is rather more variable and somewhat lower in some of the animals.

2\) The increased regeneration is similar to the increase in neuronal survival in [Figure 1](#fig1){ref-type="fig"}. Is the increase in axon number a reflection of increase of ganglion cell numbers?

3\) The combined effect of active AKT and GSKβknockout in [Figure 4](#fig4){ref-type="fig"} appears to be a significant and robust effect, which is certainly interesting.

4\) The effects of the various manipulations 2 and 3 are not large, and would be vulnerable to variable levels of transduction.

5\) The reagents used for [Figure 3](#fig3){ref-type="fig"} have overall effects on protein synthesis. To what extent do the authors ascribe their results to specific effects on axon growth rather than through effects on synthesis?

10.7554/eLife.14908.018

Author response

\[Editors' note: the author responses to the previous round of peer review follow.\]

*Reviewer \#1: My main concern about the in vivo experiments is the lack of quantification and controls with respect to the expression of the constructs, especially Akt isoforms and mutants. This raises the question of whether the effects observed are truly due to gene manipulation or due to alterations in the expression of exogenous construction at different levels. Addressing these two important gaps (quantification of cell signaling alterations and quantification of expression levels of tagged proteins) would significantly enhance the impact of this manuscript.*We appreciate Reviewer 1's recognition that our study "probe an important gap\[...\]". We thank Reviewer 1 for bring up this insightful request, quantification of expression levels of HA-tagged AKT isoforms/mutants and quantification of cell signaling alterations. We now provide this information, which we believe has substantially improved the manuscript. We realized that immunostaining of flat-mount retina is not sufficient to evaluate subtle differences in expression and alterations in signaling and that this technique will only detect an effect that is very dramatic (all or none). Therefore, we performed Western blots of retina lysates for all the conditions that we studied and quantified the HA-tag levels of AKT isoforms/mutants and signaling (phosphorylation levels of AKT-T308, S473, S6 and GSK3β-S9). We will provide more detail in our responses to individual questions below, but our overall conclusion is that the effects on axon regeneration are indeed due to gene manipulations and corresponding signaling alterations, rather than to different levels of expression of exogenous constructs. Consistent with Reviewer 1's prediction, these additional Western blot studies significantly enhanced the reliability of our results and therefore the impact of our study. More importantly, the new experiments revealed several new findings. The most significant of these is that: pAKT-T308 and mTORC2-pAKT-S473 differentially regulate GSK3β-S9 phosphorylation, through which axon regeneration is oppositely controlled by pAKT-T308 and mTORC2-pAKT-S473.

1\) If the authors are going to refer to [Figure 3C](#fig3){ref-type="fig"} in the Introduction, I suggest that they move it to [Figure 1](#fig1){ref-type="fig"}.

We agree with the reviewer that it is best not to have a model figure in the middle of the paper and we no longer refer to [Figure 3C](#fig3){ref-type="fig"} in the Introduction. [Figure 3C](#fig3){ref-type="fig"} now stands by itself as [Figure 8](#fig8){ref-type="fig"} and serves as a summary/model in the last part of the paper, as is customary for most reports.

2\) [Figure 1C](#fig1){ref-type="fig"}: The authors need to quantify expression levels of HA-tagged AKt isoforms. Also since Ser 235-236 phosphorylation is not specific to S6K, please measure phospho-S6 at Ser 240-244 (antibody available from Cell signaling).

We performed Western blots to show comparable expression levels of HA-tagged AKT isoforms in retina. In addition, because anti-pAKT-T308 antibody works well in Western blot, whereas it worked poorly in immunostaining, we were able to find that pAKT-T308 and pS6 are higher in AKT3-retina than AKT1-retina; immunostaining had not definitively revealed this difference before. However, because neither anti-pAKT-T308 nor anti-pAKT-S473 antibodies do not recognize AKT2 well in Western blots, it is difficult to compare AKT2 phosphorylation levels with AKT1 and AKT3. We thank Reviewer 1 for recommending a more reliable antibody for pS6; we repeated all the immunostaining and Western blots of pS6 with phospho-S6 S240/244 antibody, as Reviewer 1 suggested.

3\) [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}: same criticism as above. Needs quantification of Akt mutants and phospho-S6 at Ser 240-244.

We performed Western blots to show comparable expression levels of HA-tagged AKT3 WT and AKT3 mutants in retina and decreased levels of pS6 in the AKT3 mutants (see new [Figure 3](#fig3){ref-type="fig"}).

4\) [Figure 3](#fig3){ref-type="fig"}: It is especially important in this figure to know what the expression levels of Akt3 exogenous construct is in each of these conditions. The effects of mTOR or RAPTOR knockout could simply affect the expression levels of Akt3.

The original [Figure 3](#fig3){ref-type="fig"} is now [Figure 6](#fig6){ref-type="fig"}. As Reviewer 1 predicted, mTORC1 inhibition (RAPTOR or mTOR deletion, S6K1-DN or 4E-BP1-4A over-expression) did decrease AKT3 expression as shown by HA levels in Western blot. However, we argue that the decreased AKT3 may not be the reason for decreased axon regeneration, or at least not the sole reason, because the decreased AKT3 did not affect its function in RGC survival, indicating that the level of AKT3 is enough to execute its neuronal function in RGC. Although we cannot totally exclude the possibility that the decreased AKT3 contributes to the decreased axon regeneration, we consider the significant decrease in mTORC1 signaling and protein synthesis to be the main reason for the inhibition of axon regeneration. Consistent with this notion, there are other circumstances in which even though the AKT3 level is downregulated (AKT3 in RICTOR KO or GSK3β KO mice), axon regeneration is enhanced ([Figure 5](#fig5){ref-type="fig"}, [7](#fig7){ref-type="fig"}). These findings also support the idea that the level of AKT3 that can induce axon regeneration is not extremely high.

*5) [Figure 4](#fig4){ref-type="fig"}: similar concerns as above. The authors need to show and quantify the expression levels of Akt3 expression constructs in 4B, E and F.*The original [Figure 4](#fig4){ref-type="fig"} is now [Figure 7](#fig7){ref-type="fig"} and we include the quantification of AKT3 expression in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}. We also observed decreased HA-AKT3 expression after co-expression of GSK3β-S9A mutant or deletion of GSK3β. We don't know the explanation of this inhibition; it may be due to the mixed-injection of two kinds of AAVs. Again, the decreased AKT3 did not affect RGC survival and showed opposite effects on axon regeneration, depending on activation or inhibition of GSK3β. Thus we conclude that the effects on axon regeneration are due to the signaling alterations, rather than to the level of AKT expression per se.

*Reviewer \#2: In this short research report, Miao et al. focus on differential regulation of AKT→mTor pathways for CNS axon regeneration using an optic nerve crush model. The authors convincingly show that membrane targeted AKT proteins increase regeneration, with AKT2 and 3 driving higher levels of growth than AKT1. The differential effects of mTORC1 vs. mTORC2 are intriguing and, if true, have important implications for efforts in the field to augment CNS regeneration using activation of AKT→mTor pathway. Likewise, differential activity of AKT3PT305 vs. AKT3PS472 is a novel finding and a potential advance. Overall, the authors conclude that AKT3PT305→GSK3βPS9 and mTORC1→4EBP1/S6K support CNS axon regeneration while mTORC1→AKT3PS472 blocks or antagonizes axon regeneration. However, I am not convinced that the authors have proven these conclusions.*We appreciate Reviewer 2's recognition that the findings are "intriguing" and the potential "important implications" of the "novel finding". We hope that the new experiments and additional data presented in this new submission will convince Reviewer 2 of our conclusions.

*RGC death following axotomy is well established and the authors indicate that introduction of the AKTmyr isoforms increased RGC survival roughly two fold over non-transduced animals/eyes. The authors sporadically mention survival differences in the text, but show no other data beyond [Figure 1D](#fig1){ref-type="fig"}. Looking over the post-crush retina images, there is quite variable Tuj1 staining in the supplemental figures. For example, Figure 3---figure supplement 2 shows markedly different numbers of Tuj1+ cells comparing AKT3 only vs. additional AKT3 + raptor KO, S6K-DN, 4EBP1S4A(?) & mTOR KO; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"} similarly shows differences in RGC numbers with Tuj1 staining comparing the varying combinations. Considering that the authors only show naïve retina images for the AKT3 mutants and Rictor-KO, I have a very difficult time dissociating regeneration and survival based on the data presented. Obviously, the RGCs need to survive after axotomy to regenerate, but I have concern that some of the decreased regeneration here may relate to differences in survival with the AKT, mTOR, and GSK3β manipulations. The authors need to provide quantitative data for survival across these manipulations and offer clear evidence that effects are regeneration rather than RGC survival to support their conclusions. Going along with this, some of the supplemental data should likely be included in the regular figures for the manuscript.*We apologize for the inadequate RGC survival data in the original manuscript. We had collected all the RGC survival data in every condition that we tested for axon regeneration, but we did not present it in the previous version, because we wanted to save space and because we do not consider RGC survival to be a decisive factor for axon regeneration, based on our previous experience and the available literature. We now present all the quantitative RGC survival data in [Figure 2](#fig2){ref-type="fig"}, [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}, and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}.

We regret the confusing Tuj1 staining in the original figures. Our monitors did not indicate "markedly different numbers of Tuj1+ cells", although fluorescence intensity can vary from monitor to monitor, perhaps because of differences in tone calibration. We have put considerable effort into presenting the figures in a consistent fashion and counting the surviving RGCs with double-blinded methods.

We agree with Reviewer 2 that a RGC must survive to be able to regenerate its axon. However, the level of RGC survival does not seem to correlate with the degree of axon regeneration in many of the conditions that we studied. We now include a paragraph in the Discussion which reads:

"Apparently, neuronal survival is a prerequisite for axon regeneration. But we and others did not find that increased neuron survival was invariably linked with proportionately greater axon regeneration (Benowitz et al. 2015). \[...\] There are far fewer regenerating axons than surviving RGCs, however, suggesting that only a small percentage of RGCs are regenerating and different subtypes of RGCs have different regeneration abilities (Duan et al. 2015). In-depth understanding of the mechanisms of this difference will be required to maximize RGC axon regeneration."

Similar to the above issue with survival images, the immunoreactivity for pS6K and pGSK3β varies substantially across the same supplemental images and the authors seem to cherry-pick the relevance of these variations.

We agree with Reviewer 2's opinion about the inadequacies of immunostaining experiments and we have included Western blot quantification data, which are more convincing and relevant. We have learned that immunostaining can reliably detect only large differences (e.g., totally blocked, deleted or overexpressed genes), whereas Western blot can show relative quantitatively even relatively subtle signaling differences.

*With the exception of Figure 1---figure supplement 1, the authors do not show any data on wild-type retina/optic nerve. Considering that eLife presumably targets a general readership (i.e., rather than selectively neuroscience), the authors need to include data on wild-type animal responses -- or better yet, rodents transduced with a control AAV2.*

We now present WT retina and optic nerve images in [Figure 2](#fig2){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.

The authors\' conclusion that T305 and S472 phosphorylation have distinct outcomes for regeneration is quite intriguing. The schematic in [Figure 3C](#fig3){ref-type="fig"} suggests that mTORC2 has a more direct effect on attenuating axon regeneration than antagonizing phosphorylation of AKTT473. If this is the case, then why would the RICTOR KO have no effect on regeneration by itself?

We agree with Reviewer 2's interpretation, that mTORC2 might not regulate axon regeneration directly since RICTOR KO does not induce axon regeneration. Originally we considered that RICTOR deletion may just not be enough to induce axon regeneration; because we have not proven this notion, we have removed from the new [Figure 8](#fig8){ref-type="fig"} the dotted line that linked mTORC2 directly to axon regeneration in the original [Figure 3C](#fig3){ref-type="fig"}.

*Also, when the authors claim that no axon regeneration was detected in mTOR KO, RAPTOR KO, RICTOR KO, against what are the comparisons being performed? It would be useful to see the quantitation of this growth compared to both control viral transduction and wild type AKT3 -- likewise, quantitation of the axon growth with the varying AKT3 mutants should be shown.*We regret not making it clear that we consider that there is no axon regeneration when the phenotype is similar to WT mice. We now provide data, including WT optic nerve after crush injury in [Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, to show the no axon regeneration phenotype of AKT3 mutants and mTOR/RAPTOR/RICTOR deletion and the quantification data.

It is unfortunate that the anti-phospho-AKTT308 does not recognize AKT3PT305, as I think that distinguishing an intramolecular inhibition of T305 phosphorylation vs. indirect mechanisms (including intermolecular between AKT proteins) is an important distinction to make. I do not think it is necessarily needed for the current manuscript, but it would be good to know what efforts the authors made to detect AKT3PT305 as positive data could strengthen the authors\' case.

We thank Reviewer 2 for the suggestion to test anti-phospho-AKT-T308 antibody, which indeed works in Western blot. As Reviewer 2 predicted, we confirmed the activation of AKT by overexpression of constitutively active WT AKTs and the inhibition of AKT3 by the AKT3 mutants in [Figure 1](#fig1){ref-type="fig"}, [3](#fig3){ref-type="fig"} and 5. More importantly, we determined that pS473 inhibition by AKT3-S472A mutant or RICTOR KO decreases pT308. These results provide additional confirmation of our hypothesis that the increased axon regeneration induced by blocking S473 phosphorylation is not due to the increase of pT308, but to different downstream effectors or differentially regulated downstream effectors of AKT. Surprisingly, but excitingly, we found that phosphorylation of GSK3β is oppositely regulated by pT308 and pS473 ([Figure 5](#fig5){ref-type="fig"}). This finding is extremely important, but was missed from our original manuscript. We therefore greatly appreciate that both Reviewer 1 and Reviewer 2 insisted that we should explore signaling events with Western blots.

*From the work here, as well as previous observations from this group, it is not clear if the effect of modulating the AKT→mTor pathway is mediated in the perikaryon, locally in the axons/growth cones, or both. With increasing evidence for localized protein synthesis in regenerating axons and recent work showing mRNAs and translational machinery (including the mTORC1 targets studied here) in regenerating CNS axons, the authors should acknowledge the possibility of localized effects. The images for HA shown in [Figure 1](#fig1){ref-type="fig"} suggest that AKTmyr isoforms are localizing into at least the proximal axons. Do these also extend to the distal regenerating axons? This also raises the question of whether the regenerating axons shown with CTB labeling are also HA positive (i.e., for those animals expressing AKT isoforms).*This is another case in which Reviewer 2's suggestion deserves our thanks. As Reviewer 2 suggested, we investigated the translocation of AKT in optic nerve and discovered another surprising distinct phenotype ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}): pro-axon regeneration WT AKT isoforms and AKT3-S472A are distributed in optic nerve whereas no-axon regeneration AKT3-KD, AA and T305A mutants are significantly blocked from optic nerve. The mechanism for this difference and the relationship to axon regeneration are presently unclear. However, this important finding, which otherwise would be missed without Reviewer 2's thoughtful input, together with the confirmation of localization of WT AKT in regenerating axons, open a new avenue to explore in CNS axon regeneration.

Reviewer \#3:

The paper looks at AKT and GSKβ effects on regeneration in the optic nerve, assigning roles to various components of the signaling pathway.

*1) The authors state at the beginning that they achieved 90% transduction of ganglion cells, but do not appear to have measured this routinely in each case. 90% transduction over the whole retina is difficult to achieve. Moreover, some of the illustrations suggest that the transduction rate is rather more variable and somewhat lower in some of the animals.*

We have used a mutant AAV capsid plasmid to produce AAV2 that can achieve very high transducing efficiency for RGCs. We previously explained this strategy in the Methods section, and we now also note it in Results. We also now include quantification of percentages of Tuj1+ RGCs expressing HA-tagged AKTs (\> 80%). The original claim of 90% is indeed achievable but not always. We agree with Reviewer 3 that there will be variation in in vivo studies. We used the same batch of virus and the same titers across the lines to minimize the variation sufficiently for us to be confident with our results.

2\) The increased regeneration is similar to the increase in neuronal survival in [Figure 1](#fig1){ref-type="fig"}. Is the increase in axon number a reflection of increase of ganglion cell numbers?

The regenerating axons are far fewer than the surviving RGCs, and we do not think that the variation in RGC survival is the main reason for the change in axon regeneration, although we cannot totally exclude this possibility. We have explained this in detail in our response to Reviewer 2's similar comment and discuss it in the manuscript.

3\) The combined effect of active AKT and GSKβ knockout in [Figure 4](#fig4){ref-type="fig"} appears to be a significant and robust effect, which is certainly interesting.

We appreciate Reviewer 3's recognition of the significance of this finding. In the revised manuscript we further provide an explanation and exciting evidence, the less complete phosphorylation/inhibition of GSK3β by WT AKT.

4\) The effects of the various manipulations 2 and 3 are not large, and would be vulnerable to variable levels of transduction.

We are not sure what "manipulations 2 and 3" refer to. The expression levels for all the manipulations are now documented by Western blot analysis and hopefully our responses to other questions answered this question as well.

5\) The reagents used for [Figure 3](#fig3){ref-type="fig"} have overall effects on protein synthesis. To what extent do the authors ascribe their results to specific effects on axon growth rather than through effects on synthesis?

This is a good question; we addressed a similar question in our response to Reviewer 1's comments.

[^1]: These authors contributed equally to this work.
